Zovirax Rx-to-OTC switch
This article was originally published in The Tan Sheet
Executive Summary
FDA's Nonprescription Drugs and Antiviral Drugs Advisory Committees will review data on the Rx-to-OTC switch of Burroughs Wellcome's genital herpes drug Zovirax (acyclovir) at a Jan. 12 joint meeting, the agency said. Formal review of the switch application was postponed in July to allow Burroughs Wellcome to submit data addressing concerns raised at an FDA public hearing in May ("The Tan Sheet" July 4, p. 1)